Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT00001456 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Clinical and Basic Investigations Into Hermansky-Pudlak Syndrome

StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

The 50 most recent of 359 record versions are accounted for below. See every version on ClinicalTrials.gov ↗

  1. Minor Eligibility criteria expanded, about 1 word
  2. Minor 45 versions Re-verified since Sep 25, 2024, no change to tracked fieldsv314-v358
  3. Minor Study Status, Study Description, Eligibilityv313
  4. Minor 3 versions Re-verified since Sep 7, 2024, no change to tracked fieldsv310-v312
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Hermansky-Pudlak Syndrome (HPS) is an inherited disease which results in decreased pigmentation (oculocutaneous albinism), bleeding problems due to a platelet abnormality (platelet storage pool defect), and storage of an abnormal fat-protein compound (lysosomal accumulation of ceroid lipofuscin). The disease can cause poor functioning of the lungs, intestine, kidneys, or heart. The major complication of the disease is pulmonary fibrosis and typically causes death in patients ages 40 - 50 years old. The disorder is common in Puerto Rico, where many of the clinical research studies on the disease have been conducted. Neither the full extent of the disease nor the basic cause of the disease is known. There is no known treatment for HPS. The purpose of this study is to perform research into the medical complications of HPS and begin to understand what causes these complications. Researchers will clinically evaluate patients with HPS of all ethnic backgrounds. They will obtain cells, blood components (plasma), and urine for future studies. Genetic tests (mutation analysis) to detect HPS-causing genes will also be conducted.\<TAB\>...
Trial Details
NCT Number NCT00001456
Lead Sponsor National Human Genome Research Institute (NHGRI)
Conditions Hermansky-Pudlak Syndrome (HPS)
Enrollment 600 participants
Start Date
Updated on ClinicalTrials.gov